From: Altered monocyte activation markers in Tourette’s syndrome: a case–control study
n | TS patients | n | Healthy controls | |
---|---|---|---|---|
Age, mean ± SD (range) | 46 | 29.3 ± 14.1 (8–62) | 43 | 30.6 ± 13.8 (8–62) |
< 18 years, n (%) | 15 | 33% | 10 | 23% |
Age of onset, mean ± SD (range) | 46 | 8.2 ± 3.7 (2–17) | 43 | n.a. |
Male:female ratio (n) | 46 | 3.6:1 (36 m, 10 f) | 43 | 2.3:1 (30 m, 13 f) |
TSGS values, mean ± SD (range) | 46 | 40.2 ± 13.0 (16.8 - 64.3) | 43 | n.a. |
OCD, n (%), MOCI ≥12, mean ± SD (range) | 34 | 74% 13.1 ± 2.8 (12–26) | 0 | 0% |
No OCD n (%), MOCI < 12 mean ± SD (range) | 12 | 26% 0.42 ± 0.79 (0–2) | 43 | 100% 1.42 ± 0.96 (0–4) |
Psychotropic medication1, n (%) | 30 | 65% | 0 | 0% |
Not medicated | 16 | 35% | 43 | 100% |